299 related articles for article (PubMed ID: 22518841)
21. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin.
Alcorlo M; Tortajada A; Rodríguez de Córdoba S; Llorca O
Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13504-9. PubMed ID: 23901101
[TBL] [Abstract][Full Text] [Related]
22. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP).
Seya T; Okada M; Matsumoto M; Hong KS; Kinoshita T; Atkinson JP
Mol Immunol; 1991 Oct; 28(10):1137-47. PubMed ID: 1833639
[TBL] [Abstract][Full Text] [Related]
23. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact.
Pryzdial EL; Isenman DE
J Biol Chem; 1987 Feb; 262(4):1519-25. PubMed ID: 3643213
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement.
Pangburn MK; Pangburn KL; Koistinen V; Meri S; Sharma AK
J Immunol; 2000 May; 164(9):4742-51. PubMed ID: 10779780
[TBL] [Abstract][Full Text] [Related]
26. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
Waldo FB; Forristal J; Beischel L; West CD
J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
[TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2-encoded ORF8 protein possesses complement inhibitory properties.
Kumar J; Dhyani S; Kumar P; Sharma NR; Ganguly S
J Biol Chem; 2023 Mar; 299(3):102930. PubMed ID: 36682494
[TBL] [Abstract][Full Text] [Related]
28. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.
Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K
J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384
[TBL] [Abstract][Full Text] [Related]
29. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
J Exp Med; 1981 Sep; 154(3):856-67. PubMed ID: 6912277
[TBL] [Abstract][Full Text] [Related]
30. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
[TBL] [Abstract][Full Text] [Related]
31. The interaction of C3b bound to pneumococci with factor H (beta 1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement system.
Brown EJ; Joiner KA; Gaither TA; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):409-15. PubMed ID: 6223077
[TBL] [Abstract][Full Text] [Related]
32. A mechanism of activation of the alternative complement pathway by the classical pathway: protection of C3b from inactivation by covalent attachment to C4b.
Meri S; Pangburn MK
Eur J Immunol; 1990 Dec; 20(12):2555-61. PubMed ID: 2148521
[TBL] [Abstract][Full Text] [Related]
33. Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein.
McRae JL; Duthy TG; Griggs KM; Ormsby RJ; Cowan PJ; Cromer BA; McKinstry WJ; Parker MW; Murphy BF; Gordon DL
J Immunol; 2005 May; 174(10):6250-6. PubMed ID: 15879123
[TBL] [Abstract][Full Text] [Related]
34. Molecular basis of C-reactive protein binding and modulation of complement activation by factor H-related protein 4.
Hebecker M; Okemefuna AI; Perkins SJ; Mihlan M; Huber-Lang M; Józsi M
Mol Immunol; 2010 Mar; 47(6):1347-55. PubMed ID: 20042240
[TBL] [Abstract][Full Text] [Related]
35. The mechanism of activation of the alternative pathway of complement by cell-bound C4b.
Farries TC; Steuer KL; Atkinson JP
Mol Immunol; 1990 Nov; 27(11):1155-61. PubMed ID: 2247091
[TBL] [Abstract][Full Text] [Related]
36. The C3/C5 convertase of the alternative pathway of complement: stabilization and restriction of control by lanthanide ions.
Fishelson Z; Müller-Eberhard HJ
Mol Immunol; 1983 Mar; 20(3):309-15. PubMed ID: 6553181
[TBL] [Abstract][Full Text] [Related]
37. Kallikrein Cleaves C3 and Activates Complement.
Irmscher S; Döring N; Halder LD; Jo EAH; Kopka I; Dunker C; Jacobsen ID; Luo S; Slevogt H; Lorkowski S; Beyersdorf N; Zipfel PF; Skerka C
J Innate Immun; 2018; 10(2):94-105. PubMed ID: 29237166
[TBL] [Abstract][Full Text] [Related]
38. The Role of Properdin in Killing of Non-Pathogenic
Martinez APG; Abreu PAE; de Arruda Vasconcellos S; Ho PL; Ferreira VP; Saggu G; Barbosa AS; Isaac L
Front Immunol; 2020; 11():572562. PubMed ID: 33240263
[TBL] [Abstract][Full Text] [Related]
39. A novel mechanism of complement inhibition unmasked by a tick salivary protein that binds to properdin.
Tyson KR; Elkins C; de Silva AM
J Immunol; 2008 Mar; 180(6):3964-8. PubMed ID: 18322205
[TBL] [Abstract][Full Text] [Related]
40. C3b generation is affected by the structure of the O-antigen polysaccharide in lipopolysaccharide from salmonellae.
Jimenez-Lucho VE; Joiner KA; Foulds J; Frank MM; Leive L
J Immunol; 1987 Aug; 139(4):1253-9. PubMed ID: 2440949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
